Skip to main content
Top
Published in: EJNMMI Research 1/2020

Open Access 01-12-2020 | Breast Cancer | Original research

Fluorescent image-guided surgery in breast cancer by intravenous application of a quenched fluorescence activity-based probe for cysteine cathepsins in a syngeneic mouse model

Authors: Frans V. Suurs, Si-Qi Qiu, Joshua J. Yim, Carolien P. Schröder, Hetty Timmer-Bosscha, Eric S. Bensen, John T. Santini Jr, Elisabeth G. E. de Vries, Matthew Bogyo, Gooitzen M. van Dam

Published in: EJNMMI Research | Issue 1/2020

Login to get access

Abstract

Purpose

The reoperation rate for breast-conserving surgery is as high as 15–30% due to residual tumor in the surgical cavity after surgery. In vivo tumor-targeted optical molecular imaging may serve as a red-flag technique to improve intraoperative surgical margin assessment and to reduce reoperation rates. Cysteine cathepsins are overexpressed in most solid tumor types, including breast cancer. We developed a cathepsin-targeted, quenched fluorescent activity-based probe, VGT-309, and evaluated whether it could be used for tumor detection and image-guided surgery in syngeneic tumor-bearing mice.

Methods

Binding specificity of the developed probe was evaluated in vitro. Next, fluorescent imaging in BALB/c mice bearing a murine breast tumor was performed at different time points after VGT-309 administration. Biodistribution of VGT-309 after 24 h in tumor-bearing mice was compared to control mice. Image-guided surgery was performed at multiple time points tumors with different clinical fluorescent camera systems and followed by ex vivo analysis.

Results

The probe was specifically activated by cathepsins X, B/L, and S. Fluorescent imaging revealed an increased tumor-to-background contrast over time up to 15.1 24 h post probe injection. In addition, VGT-309 delineated tumor tissue during image-guided surgery with different optical fluorescent imaging camera systems.

Conclusion

These results indicate that optical fluorescent molecular imaging using the cathepsin-targeted probe, VGT-309, may improve intraoperative tumor detection, which could translate to more complete tumor resection when coupled with commercially available surgical tools and techniques.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.PubMed Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.PubMed
2.
go back to reference Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347:1227–32.PubMedCrossRef Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347:1227–32.PubMedCrossRef
3.
go back to reference Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347:1233–41.PubMedCrossRef Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347:1233–41.PubMedCrossRef
4.
go back to reference Moran MS, Schnitt SJ, Giuliano AE, Harris JR, Khan SA, Horton J, et al. Society of Surgical Oncology – American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. J Clin Oncol. 2014;32:1507–15.PubMedCrossRef Moran MS, Schnitt SJ, Giuliano AE, Harris JR, Khan SA, Horton J, et al. Society of Surgical Oncology – American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. J Clin Oncol. 2014;32:1507–15.PubMedCrossRef
5.
go back to reference Wilke LG, Czechura T, Wang C, Lapin B, Liederbach E, Winchester DP, et al. Repeat surgery after breast conservation for the treatment of stage 0 to II breast carcinoma a report from the national cancer data base, 2004-2010. JAMA Surg. 2014;149:1296–305.PubMedCrossRef Wilke LG, Czechura T, Wang C, Lapin B, Liederbach E, Winchester DP, et al. Repeat surgery after breast conservation for the treatment of stage 0 to II breast carcinoma a report from the national cancer data base, 2004-2010. JAMA Surg. 2014;149:1296–305.PubMedCrossRef
6.
go back to reference Isaacs AJ, Gemignani ML, Pusic A, Sedrakyan A. Association of breast conservation surgery for cancer with 90-day reoperation rates in New York state. JAMA Surg. 2016;151:648–55.PubMedCrossRef Isaacs AJ, Gemignani ML, Pusic A, Sedrakyan A. Association of breast conservation surgery for cancer with 90-day reoperation rates in New York state. JAMA Surg. 2016;151:648–55.PubMedCrossRef
7.
go back to reference Gray RJ, Pockaj BA, Garvey E, Blair S. Intraoperative margin management in breast-conserving surgery: a systematic review of literature. Ann Surg Oncol. 2018;25:18–27.PubMedCrossRef Gray RJ, Pockaj BA, Garvey E, Blair S. Intraoperative margin management in breast-conserving surgery: a systematic review of literature. Ann Surg Oncol. 2018;25:18–27.PubMedCrossRef
8.
go back to reference Thill M, Baumann K, Barinoff J. Intraoperative assessment of margins in breast conservative surgery - still in use? J Surg Oncol. 2014;110:15–20.PubMedCrossRef Thill M, Baumann K, Barinoff J. Intraoperative assessment of margins in breast conservative surgery - still in use? J Surg Oncol. 2014;110:15–20.PubMedCrossRef
9.
go back to reference Segal E, Prestwood TR, Van Der Linden WA, Carmi Y, Bhattacharya N, Withana N, et al. Detection of intestinal cancer by local, topical application of a quenched fluorescence probe for cysteine cathepsins. Chem Biol. 2015;22:148–58.PubMedPubMedCentralCrossRef Segal E, Prestwood TR, Van Der Linden WA, Carmi Y, Bhattacharya N, Withana N, et al. Detection of intestinal cancer by local, topical application of a quenched fluorescence probe for cysteine cathepsins. Chem Biol. 2015;22:148–58.PubMedPubMedCentralCrossRef
10.
go back to reference Whitley MJ, Cardona DM, Lazarides AL, Spasojevic I, Ferrer JM, Cahill J, et al. A mouse-human phase 1 co-clinical trial of a protease-activated fluorescent probe for imaging cancer. Sci Transl Med. 2016;8:320ra4.PubMedPubMedCentralCrossRef Whitley MJ, Cardona DM, Lazarides AL, Spasojevic I, Ferrer JM, Cahill J, et al. A mouse-human phase 1 co-clinical trial of a protease-activated fluorescent probe for imaging cancer. Sci Transl Med. 2016;8:320ra4.PubMedPubMedCentralCrossRef
11.
go back to reference Olson OC, Joyce JA. Cysteine cathepsin proteases: regulators of cancer progression and therapeutic response. Nat Rev Cancer. 2015;15:712–29.PubMedCrossRef Olson OC, Joyce JA. Cysteine cathepsin proteases: regulators of cancer progression and therapeutic response. Nat Rev Cancer. 2015;15:712–29.PubMedCrossRef
12.
go back to reference Guinec N, Dalet-Fumeron V, Pagano M. “In vitro” study of basement membrane degradation by the cysteine proteinases, cathepsins B, B-like and L. digestion of collagen IV, laminin, fibronectin, and release of gelatinase activities from basement membrane fibronectin. Biol Chem Hoppe Seyler. 1993;374:1135–46.PubMedCrossRef Guinec N, Dalet-Fumeron V, Pagano M. “In vitro” study of basement membrane degradation by the cysteine proteinases, cathepsins B, B-like and L. digestion of collagen IV, laminin, fibronectin, and release of gelatinase activities from basement membrane fibronectin. Biol Chem Hoppe Seyler. 1993;374:1135–46.PubMedCrossRef
13.
go back to reference Gocheva V, Wang HW, Gadea BB, Shree T, Hunter KE, Garfall AL, et al. IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes Dev. 2010;24:241–55.PubMedPubMedCentralCrossRef Gocheva V, Wang HW, Gadea BB, Shree T, Hunter KE, Garfall AL, et al. IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes Dev. 2010;24:241–55.PubMedPubMedCentralCrossRef
14.
15.
go back to reference Watzke A, Kosec G, Kindermann M, Jeske V, Nestler HP, Turk V, et al. Selective activity-based probes for cysteine cathepsins. Angew Chemie - Int Ed. 2008;47:406–9.CrossRef Watzke A, Kosec G, Kindermann M, Jeske V, Nestler HP, Turk V, et al. Selective activity-based probes for cysteine cathepsins. Angew Chemie - Int Ed. 2008;47:406–9.CrossRef
16.
go back to reference Verdoes M, Bender KO, Segal E, van der Linden WA, Syed S, Withana NP, et al. Improved quenched fluorescent probe for imaging of cysteine cathepsin activity. J Am Chem Soc. 2013;135:14726–30.PubMedCrossRef Verdoes M, Bender KO, Segal E, van der Linden WA, Syed S, Withana NP, et al. Improved quenched fluorescent probe for imaging of cysteine cathepsin activity. J Am Chem Soc. 2013;135:14726–30.PubMedCrossRef
17.
go back to reference Withana NP, Garland M, Verdoes M, Ofori LO, Segal E, Bogyo M. Labeling of active proteases in fresh-frozen tissues by topical application of quenched activity-based probes. Nat Protoc. 2016;11:184–91.PubMedCrossRef Withana NP, Garland M, Verdoes M, Ofori LO, Segal E, Bogyo M. Labeling of active proteases in fresh-frozen tissues by topical application of quenched activity-based probes. Nat Protoc. 2016;11:184–91.PubMedCrossRef
18.
go back to reference Chauhan SS, Goldstein LJ, Gottesman MM. Expression of cathepsin L in human tumors. Cancer Res. 1991;51:1478–81.PubMed Chauhan SS, Goldstein LJ, Gottesman MM. Expression of cathepsin L in human tumors. Cancer Res. 1991;51:1478–81.PubMed
20.
go back to reference van Dam GM, Themelis G, Crane LMA, Harlaar NJ, Pleijhuis RG, Kelder W, et al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results. Nat Med. 2011;17:1315–9.PubMedCrossRef van Dam GM, Themelis G, Crane LMA, Harlaar NJ, Pleijhuis RG, Kelder W, et al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results. Nat Med. 2011;17:1315–9.PubMedCrossRef
21.
go back to reference Terwisscha van Scheltinga AGT, van Dam GM, Nagengast WB, Ntziachristos V, Hollema H, Herek JL, et al. Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies. J Nucl Med. 2011;52:1778–85.PubMedCrossRef Terwisscha van Scheltinga AGT, van Dam GM, Nagengast WB, Ntziachristos V, Hollema H, Herek JL, et al. Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies. J Nucl Med. 2011;52:1778–85.PubMedCrossRef
22.
go back to reference Warram JM, De Boer E, Korb M, Hartman Y, Kovar J, Markert JM, et al. Fluorescence-guided resection of experimental malignant glioma using cetuximab-IRDye 800CW. Br J Neurosurg. 2015;29:850–8.PubMedPubMedCentralCrossRef Warram JM, De Boer E, Korb M, Hartman Y, Kovar J, Markert JM, et al. Fluorescence-guided resection of experimental malignant glioma using cetuximab-IRDye 800CW. Br J Neurosurg. 2015;29:850–8.PubMedPubMedCentralCrossRef
23.
go back to reference Rosenthal EL, Warram JM, De Boer E, Chung TK, Korb ML, Brandwein-Gensler M, et al. Safety and tumor specificity of cetuximab-IRDye800 for surgical navigation in head and neck cancer. Clin Cancer Res. 2015;21:3658–66.PubMedPubMedCentralCrossRef Rosenthal EL, Warram JM, De Boer E, Chung TK, Korb ML, Brandwein-Gensler M, et al. Safety and tumor specificity of cetuximab-IRDye800 for surgical navigation in head and neck cancer. Clin Cancer Res. 2015;21:3658–66.PubMedPubMedCentralCrossRef
24.
go back to reference Burggraaf J, Kamerling IMC, Gordon PB, Schrier L, De Kam ML, Kales AJ, et al. Detection of colorectal polyps in humans using an intravenously administered fluorescent peptide targeted against c-met. Nat Med. 2015;21:955–61.PubMedCrossRef Burggraaf J, Kamerling IMC, Gordon PB, Schrier L, De Kam ML, Kales AJ, et al. Detection of colorectal polyps in humans using an intravenously administered fluorescent peptide targeted against c-met. Nat Med. 2015;21:955–61.PubMedCrossRef
25.
go back to reference Lamberts LE, Koch M, De Jong JS, Adams ALL, Glatz J, Kranendonk MEG, et al. Tumor-specific uptake of fluorescent bevacizumab-IRDye800CW microdosing in patients with primary breast cancer: a phase I feasibility study. Clin Cancer Res. 2017;23:2730–41.PubMedCrossRef Lamberts LE, Koch M, De Jong JS, Adams ALL, Glatz J, Kranendonk MEG, et al. Tumor-specific uptake of fluorescent bevacizumab-IRDye800CW microdosing in patients with primary breast cancer: a phase I feasibility study. Clin Cancer Res. 2017;23:2730–41.PubMedCrossRef
26.
go back to reference Nagengast WB, Hartmans E, Garcia-Allende PB, Peters FTM, Linssen MD, Koch M, et al. Near-infrared fluorescence molecular endoscopy detects dysplastic oesophageal lesions using topical and systemic tracer of vascular endothelial growth factor a. Gut. 2019;68:7–10.PubMedCrossRef Nagengast WB, Hartmans E, Garcia-Allende PB, Peters FTM, Linssen MD, Koch M, et al. Near-infrared fluorescence molecular endoscopy detects dysplastic oesophageal lesions using topical and systemic tracer of vascular endothelial growth factor a. Gut. 2019;68:7–10.PubMedCrossRef
27.
go back to reference Harlaar NJ, Koller M, De JSJ, Van LBL, Hemmer PH, Kruij S, et al. Molecular fluorescence-guided surgery of peritoneal carcinomatosis of colorectal origin: a single-Centre feasibility study. Lancet Gastroenterol Hepatol. 2016;1:283–90.PubMedCrossRef Harlaar NJ, Koller M, De JSJ, Van LBL, Hemmer PH, Kruij S, et al. Molecular fluorescence-guided surgery of peritoneal carcinomatosis of colorectal origin: a single-Centre feasibility study. Lancet Gastroenterol Hepatol. 2016;1:283–90.PubMedCrossRef
28.
go back to reference Koller M, Qiu SQ, Linssen MD, Jansen L, Kelder W, de Vries J, et al. Implementation and benchmarking of a novel analytical framework to clinically evaluate tumor-specific fluorescent tracers. Nat Commun. 2018;9:3739.PubMedPubMedCentralCrossRef Koller M, Qiu SQ, Linssen MD, Jansen L, Kelder W, de Vries J, et al. Implementation and benchmarking of a novel analytical framework to clinically evaluate tumor-specific fluorescent tracers. Nat Commun. 2018;9:3739.PubMedPubMedCentralCrossRef
29.
go back to reference Li D, Zhang J, Chi C, Xiao X, Wang J, Lang L, et al. First-in-human study of PET and optical dual-modality image-guided surgery in glioblastoma using 68Ga-IRDye800CW-BBN. Theranostics. 2018;8:2508–20.PubMedPubMedCentralCrossRef Li D, Zhang J, Chi C, Xiao X, Wang J, Lang L, et al. First-in-human study of PET and optical dual-modality image-guided surgery in glioblastoma using 68Ga-IRDye800CW-BBN. Theranostics. 2018;8:2508–20.PubMedPubMedCentralCrossRef
30.
go back to reference Ter Weele EJ, Terwisscha Van Scheltinga AGT, Linssen MD, Nagengast WB, Lindner I, Jorritsma-Smit A, et al. Development, preclinical safety, formulation, and stability of clinical grade bevacizumab-800CW, a new near infrared fluorescent imaging agent for first in human use. Eur J Pharm Biopharm. 2016;104:226–34.PubMedCrossRef Ter Weele EJ, Terwisscha Van Scheltinga AGT, Linssen MD, Nagengast WB, Lindner I, Jorritsma-Smit A, et al. Development, preclinical safety, formulation, and stability of clinical grade bevacizumab-800CW, a new near infrared fluorescent imaging agent for first in human use. Eur J Pharm Biopharm. 2016;104:226–34.PubMedCrossRef
31.
go back to reference Linssen MD, ter Weele EJ, Allersma DP, Lub-de Hooge MN, van Dam GM, Jorritsma-Smit A, et al. Roadmap for the development and clinical translation of optical tracers cetuximab-800CW and trastuzumab-800CW. J Nucl Med. 2019;60:418–23.PubMedCrossRef Linssen MD, ter Weele EJ, Allersma DP, Lub-de Hooge MN, van Dam GM, Jorritsma-Smit A, et al. Roadmap for the development and clinical translation of optical tracers cetuximab-800CW and trastuzumab-800CW. J Nucl Med. 2019;60:418–23.PubMedCrossRef
32.
go back to reference Zhang J, Mao F, Niu G, Peng L, Lang L, Li F, et al. 68 Ga-BBN-RGD PET/CT for GRPR and integrin αvβ3 imaging in patients with breast cancer. Theranostics. 2018;8:1121–30.PubMedPubMedCentralCrossRef Zhang J, Mao F, Niu G, Peng L, Lang L, Li F, et al. 68 Ga-BBN-RGD PET/CT for GRPR and integrin αvβ3 imaging in patients with breast cancer. Theranostics. 2018;8:1121–30.PubMedPubMedCentralCrossRef
33.
go back to reference Mitri Z, Constantine T, O’Regan R. The HER2 receptor in breast cancer: pathophysiology, clinical use, and new advances in therapy. Chemother Res Pract. 2012;2012:743193.PubMedPubMedCentral Mitri Z, Constantine T, O’Regan R. The HER2 receptor in breast cancer: pathophysiology, clinical use, and new advances in therapy. Chemother Res Pract. 2012;2012:743193.PubMedPubMedCentral
34.
go back to reference Morgat C, MacGrogan G, Brouste V, Vélasco V, Sévenet N, Bonnefoi H, et al. Expression of gastrin-releasing peptide receptor in breast cancer and its association with pathologic, biologic, and clinical parameters: a study of 1,432 primary tumors. J Nucl Med. 2017;58:1401–7.PubMedCrossRef Morgat C, MacGrogan G, Brouste V, Vélasco V, Sévenet N, Bonnefoi H, et al. Expression of gastrin-releasing peptide receptor in breast cancer and its association with pathologic, biologic, and clinical parameters: a study of 1,432 primary tumors. J Nucl Med. 2017;58:1401–7.PubMedCrossRef
35.
go back to reference Sevenich L, Bowman RL, Mason SD, Quail DF, Rapaport F, Elie BT, et al. Analysis of tumour- and stroma-supplied proteolytic networks reveals a brain-metastasis-promoting role for cathepsin S. Nat Cell Biol. 2014;16:876–88.PubMedPubMedCentralCrossRef Sevenich L, Bowman RL, Mason SD, Quail DF, Rapaport F, Elie BT, et al. Analysis of tumour- and stroma-supplied proteolytic networks reveals a brain-metastasis-promoting role for cathepsin S. Nat Cell Biol. 2014;16:876–88.PubMedPubMedCentralCrossRef
37.
go back to reference König L, Mairinger FD, Hoffmann O, Bittner AK, Schmid KW, Kimmig R, et al. Dissimilar patterns of tumor-infiltrating immune cells at the invasive tumor front and tumor center are associated with response to neoadjuvant chemotherapy in primary breast cancer. BMC Cancer. 2019;19:120.PubMedPubMedCentralCrossRef König L, Mairinger FD, Hoffmann O, Bittner AK, Schmid KW, Kimmig R, et al. Dissimilar patterns of tumor-infiltrating immune cells at the invasive tumor front and tumor center are associated with response to neoadjuvant chemotherapy in primary breast cancer. BMC Cancer. 2019;19:120.PubMedPubMedCentralCrossRef
38.
go back to reference Ofori LO, Withana NP, Prestwood TR, Verdoes M, Brady JJ, Winslow MM, et al. Design of protease activated optical contrast agents that exploit a latent lysosomotropic effect for use in fluorescence-guided surgery. ACS Chem Biol. 2015;10:1977–88.PubMedPubMedCentralCrossRef Ofori LO, Withana NP, Prestwood TR, Verdoes M, Brady JJ, Winslow MM, et al. Design of protease activated optical contrast agents that exploit a latent lysosomotropic effect for use in fluorescence-guided surgery. ACS Chem Biol. 2015;10:1977–88.PubMedPubMedCentralCrossRef
39.
go back to reference Yim JJ, Tholen M, Klaassen A, Sorger J, Bogyo M. Optimization of a protease activated probe for optical surgical navigation. Mol Pharm. 2018;15:750–8.PubMedCrossRef Yim JJ, Tholen M, Klaassen A, Sorger J, Bogyo M. Optimization of a protease activated probe for optical surgical navigation. Mol Pharm. 2018;15:750–8.PubMedCrossRef
40.
go back to reference Verdoes M, Edgington LE, Scheeren FA, Leyva M, Blum G, Weiskopf K, et al. A nonpeptidic cathepsin s activity-based probe for noninvasive optical imaging of tumor-associated macrophages. Chem Biol. 2012;19:619–28.PubMedPubMedCentralCrossRef Verdoes M, Edgington LE, Scheeren FA, Leyva M, Blum G, Weiskopf K, et al. A nonpeptidic cathepsin s activity-based probe for noninvasive optical imaging of tumor-associated macrophages. Chem Biol. 2012;19:619–28.PubMedPubMedCentralCrossRef
41.
go back to reference Hu HY, Vats D, Vizovisek M, Kramer L, Germanier C, Wendt KU, et al. In vivo imaging of mouse tumors by a lipidated cathepsin S substrate. Angew Chemie - Int Ed Eng. 2014;53:7669–73.CrossRef Hu HY, Vats D, Vizovisek M, Kramer L, Germanier C, Wendt KU, et al. In vivo imaging of mouse tumors by a lipidated cathepsin S substrate. Angew Chemie - Int Ed Eng. 2014;53:7669–73.CrossRef
42.
go back to reference Kramer L, Renko M, Završnik J, Turk D, Seeger MA, Vasiljeva O, et al. Non-invasive in vivo imaging of tumour-associated cathepsin B by a highly selective inhibitory DARPin. Theranostics. 2017;7:2806–21.PubMedPubMedCentralCrossRef Kramer L, Renko M, Završnik J, Turk D, Seeger MA, Vasiljeva O, et al. Non-invasive in vivo imaging of tumour-associated cathepsin B by a highly selective inhibitory DARPin. Theranostics. 2017;7:2806–21.PubMedPubMedCentralCrossRef
43.
go back to reference Poreba M, Rut W, Vizovisek M, Groborz K, Kasperkiewicz P, Finlay D, et al. Selective imaging of cathepsin L in breast cancer by fluorescent activity-based probes. Chem Sci. 2018;9:2113–29.PubMedPubMedCentralCrossRef Poreba M, Rut W, Vizovisek M, Groborz K, Kasperkiewicz P, Finlay D, et al. Selective imaging of cathepsin L in breast cancer by fluorescent activity-based probes. Chem Sci. 2018;9:2113–29.PubMedPubMedCentralCrossRef
44.
go back to reference Smith BL, Gadd MA, Lanahan CR, Rai U, Tang R, Rice-Stitt T, et al. Real-time, intraoperative detection of residual breast cancer in lumpectomy cavity walls using a novel cathepsin-activated fluorescent imaging system. Breast Cancer Res Treat. 2018;171:413–20.PubMedPubMedCentralCrossRef Smith BL, Gadd MA, Lanahan CR, Rai U, Tang R, Rice-Stitt T, et al. Real-time, intraoperative detection of residual breast cancer in lumpectomy cavity walls using a novel cathepsin-activated fluorescent imaging system. Breast Cancer Res Treat. 2018;171:413–20.PubMedPubMedCentralCrossRef
45.
go back to reference Jedeszko C, Sloane BF. Cysteine cathepsins in human cancer. Biol Chem. 2004;(11):1017–27. Jedeszko C, Sloane BF. Cysteine cathepsins in human cancer. Biol Chem. 2004;(11):1017–27.
Metadata
Title
Fluorescent image-guided surgery in breast cancer by intravenous application of a quenched fluorescence activity-based probe for cysteine cathepsins in a syngeneic mouse model
Authors
Frans V. Suurs
Si-Qi Qiu
Joshua J. Yim
Carolien P. Schröder
Hetty Timmer-Bosscha
Eric S. Bensen
John T. Santini Jr
Elisabeth G. E. de Vries
Matthew Bogyo
Gooitzen M. van Dam
Publication date
01-12-2020
Publisher
Springer Berlin Heidelberg
Published in
EJNMMI Research / Issue 1/2020
Electronic ISSN: 2191-219X
DOI
https://doi.org/10.1186/s13550-020-00688-0

Other articles of this Issue 1/2020

EJNMMI Research 1/2020 Go to the issue